Literature DB >> 11423579

Management of patients with chronic renal insufficiency in the Northeastern United States.

Annamaria T Kausz1, Samina S Khan1, Rekha Abichandani1, Waqar H Kazmi1, Gregorio T Obrador1, Robin Ruthazer2, Brian J G Pereira1.   

Abstract

Comorbid conditions that develop during chronic renal insufficiency (CRI) contribute to the high morbidity and mortality among patients with end-stage renal disease (ESRD). Thus, appropriate management during CRI may lead to improved ESRD outcomes. A retrospective cohort study was performed to describe the management of patients with CRI. A total of 602 patients with CRI (creatinine > or =1.5 mg/dl for women and > or =2.0 mg/dl for men) were seen between October 1994 and September 1998 at five nephrology outpatient clinics in the Boston area. The mean (SD) age of the patients was 63 (15.5) yr, and 53% were male. At the first nephrology visit, mean (SD) serum creatinine was 3.2 (1.6) mg/dl, and mean (SD) predicted GFR was 22.3 (8.9) ml/min per 1.73 m(2). Laboratory tests for iron levels were performed in only 18% of patients, serum parathyroid hormone levels were obtained in only 15%, lipid studies were obtained in fewer than half, and among patients with diabetes, only 28% had a glycosylated hemoglobin level measured. A hematocrit <30% was present in 38%, and abnormal calcium-phosphorus metabolism was noted in 55%. Only 59% of patients who had hematocrit <30% received recombinant human erythropoietin. Among patients who received recombinant human erythropoietin, only 47% received iron. Angiotensin-converting enzyme inhibitor use was recorded for only 65% of patients with diabetes (49% of patients overall). Among patients who were known to have progressed to ESRD, only 41% had permanent access placed before initiation of dialysis. There seems to be room for improvement in the management of patients with CRI, which could result in a slower rate of progression of CRI and reduced severity of comorbid conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11423579     DOI: 10.1681/ASN.V1271501

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  26 in total

1.  Multidisciplinary team care may slow the rate of decline in renal function.

Authors:  Elizabeth A Bayliss; Bharati Bhardwaja; Colleen Ross; Arne Beck; Diane M Lanese
Journal:  Clin J Am Soc Nephrol       Date:  2011-01-27       Impact factor: 8.237

2.  Metabolic control and vascular diseases under oral antidiabetic drug versus insulin therapy and/or diet alone during the first year of hemodialysis in type 2 diabetic patients with ESRD.

Authors:  Georg Biesenbach; Gert Bodlaj; Stephan Ebner; Peter Biesenbach; Herwig Pieringer
Journal:  Int Urol Nephrol       Date:  2010-07-20       Impact factor: 2.370

3.  Clinical testing patterns and cost implications of variation in the evaluation of CKD among US physicians.

Authors:  Raquel F Charles; Neil R Powe; Bernard G Jaar; Misty U Troll; Rulan S Parekh; L Ebony Boulware
Journal:  Am J Kidney Dis       Date:  2009-04-15       Impact factor: 8.860

4.  Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation.

Authors:  Thomas J Hogan; William J Elliott; Arnold H Seto; George L Bakris
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

5.  Evaluation of the URiSCAN super cassette ACR semiquantitative urine dipstick for microalbuminuria screening.

Authors:  Min-Chul Cho; Misuk Ji; So Young Kim; Wonho Choe; Woochang Lee; Sail Chun; Won-Ki Min
Journal:  J Clin Lab Anal       Date:  2014-02-27       Impact factor: 2.352

6.  Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.

Authors:  Steven Fishbane; Bhupinder Singh; Seema Kumbhat; Wayne A Wisemandle; Nancy E Martin
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-19       Impact factor: 8.237

7.  Recommendations for a clinical decision support for the management of individuals with chronic kidney disease.

Authors:  Meenal B Patwardhan; Kensaku Kawamoto; David Lobach; Uptal D Patel; David B Matchar
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-28       Impact factor: 8.237

8.  Renal function and risk factors of moderate to severe chronic kidney disease in Golestan Province, northeast of Iran.

Authors:  Iraj Najafi; Fatemeh Attari; Farhad Islami; Ramin Shakeri; Fatemeh Malekzadeh; Rasool Salahi; Mina Yapan Gharavi; Mostafa Hosseini; Behrooz Broumand; Ali Nobakht Haghighi; Bagher Larijani; Reza Malekzadeh
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

9.  Establishing a renal management clinic in China: initiative, challenges, and opportunities.

Authors:  Ai-Hua Zhang; Hui Zhong; Wen Tang; Shao-Yan Chen; Lian He; Song Wang; Chun Yan Su; Xin-Hong Lu; Tao Wang
Journal:  Int Urol Nephrol       Date:  2008-09-03       Impact factor: 2.370

10.  Ferumoxytol for treating iron deficiency anemia in CKD.

Authors:  Bruce S Spinowitz; Annamaria T Kausz; Jovanna Baptista; Sylvia D Noble; Renuka Sothinathan; Marializa V Bernardo; Louis Brenner; Brian J G Pereira
Journal:  J Am Soc Nephrol       Date:  2008-06-04       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.